Evidence map›Paper›PMID 34948105›Full record

ArticleInternational journal of molecular sciences2021

Cell Penetrating Peptide-Based Self-Assembly for PD-L1 Targeted Tumor Regression.

Feng Guo, Junfeng Ke, Zhengdong Fu, Wenzhao Han, Liping Wang

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 8 citations in OpenAlex.

  1. Hypericin-mediated photodynamic therapy inhibits metastasis and EMT of colorectal cancer cells by regulating RhoA-ROCK1 signaling pathway.Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology · 2024
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Feng GuoKey Laboratory for Molecular Enzymology and Engineering, Ministry of Education, Jilin University, Changchun 130012, China.
Junfeng KeKey Laboratory for Molecular Enzymology and Engineering, Ministry of Education, Jilin University, Changchun 130012, China.
Zhengdong FuKey Laboratory for Molecular Enzymology and Engineering, Ministry of Education, Jilin University, Changchun 130012, China.
Wenzhao HanKey Laboratory for Molecular Enzymology and Engineering, Ministry of Education, Jilin University, Changchun 130012, China.
Liping WangKey Laboratory for Molecular Enzymology and Engineering, Ministry of Education, Jilin University, Changchun 130012, China.
Jilin University · CN

Funding

the Science and Technology Development Program of Jilin Province No.20200404114YY, No. 20200301029RQ
6 · The paper itself

Abstract

Cell penetrating peptides (CPPs) are peptides that can directly adapt to cell membranes and then permeate into cells. CPPs are usually covalently linked to the surface of nanocarriers to endow their permeability to the whole system. However, hybrids with lipids or polymers make the metabolism much more sophisticated and even more difficult to determine. In this study, we present a continuous sequence of 18 amino acids (FFAARTMIWY(d-P)GAWYKRI). It forms nanospheres around 170 nm, which increase slightly after loading with siRNA and DOX. Notably, it can be internalized by cancer cells mainly through electronic interactions and PD-L1-mediated endocytosis. Compared with poly-l-lysine and polyethyleneimine, it has a much higher efficiency (about four times) of gene transduction while lowering toxicity. In the treatment of cancer, it causes apoptosis (21%) and inhibits the expression of SURVIVIN protein in vitro. In vivo, it shows good biocompatibility as there are no changes in mice's body weight. When administering peptide-siRNA-DOX, tumor growth is inhibited the most (about three times). These results above prove the sequence to be a good candidate for gene therapy and drug delivery.

Indexed as

Cell-Penetrating PeptidesDoxorubicinDrug Delivery SystemsEndocytosisNanospheresRNA, Small InterferingAnimalsB7-H1 AntigenCell Line, TumorFemaleHumansMiceMice, Inbred BALB CMice, NudeNeoplasm ProteinsNeoplasmsB7-H1 AntigenBIRC5 protein, humanCD274 protein, humanCell-Penetrating PeptidesDoxorubicinNeoplasm ProteinsRNA, Small InterferingSurvivingene therapyPD-L1peptideself-assembly

Identifiers

PMID34948105
PMCPMC8703959
OpenAlexW4200595468

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.